Literature DB >> 864009

The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.

S D Revak, C G Cochrane, J H Griffin.   

Abstract

The ability of human Hageman factor (coagulation factor XII) to bind to a glass surface and its susceptibility to limited proteolytic cleavage during the contact activation of plasma have been studied using normal human plasma and plasmas genetically deficient in factor XI, prekallikrein, or high molecular weight kininogen (HMWK). When diluted normal plasma containing (125)I-Hageman factor was exposed to a glass surface for varying times, the Hageman factor was found to bind to the surface, and within 5 min became maximally cleaved from its native 80,000 mol wt to yield fragments of 52,000 and 28,000 mol wt. Hageman factor in factor XI-deficient plasma behaved similarly. In prekallikrein-deficient plasma, the binding of Hageman factor to the glass surface occurred at the same rate as in normal plasma but the cleavage was significantly slower, and did not reach maximum until 60 min of incubation. Cleavage of Hageman factor in HMWK-deficient plasma occurred at an even slower rate, with greater than 110 min of incubation required for maximal cleavage, although the rate of binding to the glass was again the same as in normal plasma. Normal rates of cleavage of Hageman factor were observed for the deficient plasmas after reconstitution with purified human prekallikrein or HMWK, respectively. These observations suggest that normal contact activation in plasma is associated with proteolytic activation of surfacebound Hageman factor. The cleavage of the surface-bound Hageman factor molecule responsible for the formation of the 52,000-and 28,000-mol wt fragments occurred at two closely situated sites, one of which was within a disulfide loop. Cleavage at the site external to the disulfide bond resulted in the release from the surface of the 28,000-mol wt fragment. Cleavage at the site within the disulfide loop resulted in the formation of a 28,000-mol wt fragment which remained surface bound, presumably by virtue of the disulfide linkage to the larger fragment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 864009      PMCID: PMC372330          DOI: 10.1172/JCI108741

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.

Authors:  A S Weiss; J I Gallin; A P Kaplan
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  Preparation, characterization, and activation of a highly purified factor XI: evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII.

Authors:  S Schiffman; P Lee
Journal:  Br J Haematol       Date:  1974-05       Impact factor: 6.998

3.  Structural changes accompanying enzymatic activation of human Hageman factor.

Authors:  S D Revak; C G Cochrane; A R Johnston; T E Hugli
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

4.  Isolation of two functionally different kininogens from human plasma--separation from proteinase inhibitors and interaction with plasma kallikrein.

Authors:  F M Habal; H Z Movat; C E Burrowes
Journal:  Biochem Pharmacol       Date:  1974-08-15       Impact factor: 5.858

5.  Effect of plasma kallikrein on coagulation in vitro.

Authors:  K D Wuepper; C G Cochrane
Journal:  Proc Soc Exp Biol Med       Date:  1972-10

6.  A pre-albumin activator of prekallikrein.

Authors:  A P Kaplan; K F Austen
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

7.  Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties.

Authors:  W E Hathaway; L P Belhasen; H S Hathaway
Journal:  Blood       Date:  1965-11       Impact factor: 22.113

8.  The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor).

Authors:  C G Cochrane; K D Wuepper
Journal:  J Exp Med       Date:  1971-10-01       Impact factor: 14.307

9.  Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein.

Authors:  C G Cochrane; S D Revak; K D Wuepper
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

10.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

View more
  27 in total

1.  Amidolytic, procoagulant, and activation-suppressing proteins produced by contact activation of blood factor XII in buffer solution.

Authors:  Avantika Golas; Chyi-Huey Joshua Yeh; Christopher A Siedlecki; Erwin A Vogler
Journal:  Biomaterials       Date:  2011-09-28       Impact factor: 12.479

Review 2.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Association of factor XI and high molecular weight kininogen in human plasma.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

4.  Release of elastase from purified human lung mast cells and basophils. Identification as a Hageman factor cleaving enzyme.

Authors:  H L Meier; E S Schulman; L W Heck; D MacGlashan; H H Newball; A P Kaplan
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

5.  Amidolytic properties of single-chain activated Hageman factor.

Authors:  O D Ratnoff; H Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

6.  Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.

Authors:  O D Ratnoff; H Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

7.  A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Authors:  Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani
Journal:  Thromb Res       Date:  2016-02-18       Impact factor: 3.944

8.  Immobilized transition metal ions stimulate contact activation and drive factor XII-mediated coagulation.

Authors:  N J Mutch; E K Waters; J H Morrissey
Journal:  J Thromb Haemost       Date:  2012-10       Impact factor: 5.824

9.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

10.  Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.

Authors:  Yves Decrem; Géraldine Rath; Virginie Blasioli; Philippe Cauchie; Séverine Robert; Jérôme Beaufays; Jean-Marie Frère; Olivier Feron; Jean-Michel Dogné; Chantal Dessy; Luc Vanhamme; Edmond Godfroid
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.